PF-Atlas › Clinical Trials › NCT03475381

Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor

Ivacaftor+lumacaftor · Not specified

Registry ID
NCT03475381
Phase
Not specified
Status
Completed
Drug / intervention
Ivacaftor+lumacaftor
Sponsor
Assistance Publique - Hôpitaux de Paris
Start
2016-01-22
Enrollment
852
Locations
1

About this trial

The purpose of the study is to examine the real-life safety and effectiveness of the novel combination ivacaftor+lumacaftor in eligible patients with cystic fibrosis (CF). All patients with CF were eligible if they were 12 years and older, started ivacaftor+lumacaftor outside of a clinical trial between December 15th 2017 and December 15th 2018 in an accredited CF center in France. Patient followed-up is based on standardized recommendation of the French Cystic Fibrosis Society. Each patient is followed 1 year.

View NCT03475381 on ClinicalTrials.gov →

Explore related

All Ivacaftor+lumacaftor trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03475381 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.